TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03574649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin
Description: INNO-206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: carboplatin
Study: NCT00282009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Internet
Description: Basic Internet control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet
Description: enhanced Internet cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet + phone
Description: enhanced Internet plus proactive telephone counseling
Study: NCT02122822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: vaccination of autologous gp96 derived from tumor tissue + basal treatment
Study: NCT00762853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush half mouth once with assigned study treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride and triclosan
Description: Brush half mouth once with assigned study treatment
Study: NCT02973789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitors or docetaxel
Description: Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Study: NCT03795792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Will be provided in capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrolyzed collagen
Description: Will be provided in capsules.
Study: NCT01196741

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib
Description: Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
Study: NCT01998334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH 6h
Description: CVVH 6h for first three days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH 10h
Description: CVVH 10h for first three days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVHDF 6h
Description: CVVHDF 6h for first three days
Study: NCT01596777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
Study: NCT02973789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors or docetaxel
Description: Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Study: NCT04408625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3884963
Description: Participants will receive a single dose of LY3884963, administered intra cisterna magna

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3884963
Description: Participants will receive a single dose of LY3884963, administered intra cisterna magna
Study: NCT01596777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide placebo
Description: 200 ml apple juice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylnaltrexone placebo
Description: Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylnaltrexone placebo
Description: Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone 12 mg sc.
Description: RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone IR capsule
Description: Methylnaltrexone bromide 500 mg IR capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone ER capsule
Description: Methylnaltrexone bromide 500 mg ER capsule

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
Study: NCT01596777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)
Study: NCT03029689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Current ART
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Current ART
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI
Study: NCT02817685

Intervention type: OTHER
Intervention: 3 months

Intervention type: OTHER
Intervention: 3 months

Intervention type: OTHER
Intervention: 6 months

Intervention type: OTHER
Intervention: 6 months

Intervention type: OTHER
Intervention: 6 months

Intervention type: OTHER
Intervention: 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI
Study: NCT03819647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stiripentol (Diacomit)
Description: Administration of stiripentol per os
Study: NCT04677985

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menthol based topical analgesic
Description: Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Menthol based topical analgesic
Description: Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
Study: NCT04408625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV pulses every 2 weeks in the first 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV pulses every 2 weeks in the first 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV pulses every 2 weeks in the first 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV pulses every 2 weeks in the first 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Sirolimus
Description: At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Sirolimus
Description: At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Sirolimus
Description: At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Sirolimus
Description: At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Prednisone
Description: If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Prednisone
Description: If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Prednisone
Description: If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Prednisone
Description: If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
Study: NCT02876185

Intervention type: OTHER
Intervention: Monitoring by an orthoptist then by an ophthalmologist
Description: At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
Study: NCT00570492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Description: Fluticasone furoate nasal spray 110mg QD
Study: NCT02392481

Intervention type: PROCEDURE
Intervention: Biofluid sampling
Study: NCT02385474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12% SDF
Description: 12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12% SDF
Description: 12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF
Description: 38% silver diamine fluoride solution, of which the capability of arresting dental caries is known

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF
Description: 38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
Study: NCT03334513

Intervention type: DRUG
Intervention: Bevacizumab
Description: intravitreal injection of bevacizumab

Intervention type: DRUG
Intervention: Ranibizumab
Description: intravitreal injection of ranibizumab
Study: NCT01110018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (SOLUTION)
Description: 20μg /mL solution for IV and Oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (SOLUTION)
Description: 20μg /mL solution for IV and Oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (SOLUTION)
Description: 20μg /mL solution for IV and Oral dosing
Study: NCT00103740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements
Description: Calcium and vitamin D supplements were supplied
Study: NCT01288001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ostenil plus
Description: 2% Sodium Hyaluronate plus Mannitol injection
Study: NCT00519051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)
Description: Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
Study: NCT03419988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 24 sessions of aerobic exercise
Study: NCT00880295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic carpal tunnel release
Description: endoscopic surgery, which is standard of care for carpal tunnel release
Study: NCT01110018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (SOLUTION)
Description: 20μg /mL solution for IV and Oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (INHALATION POWDER)
Description: 500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
Study: NCT03612921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral Amantadine sulfate
Description: oral amantadine
Study: NCT00570492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray
Study: NCT00880295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open carpal tunnel release
Description: open surgery, which is standard of care for carpal tunnel release
Study: NCT03580681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
Study: NCT04306263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched infant formula
Description: Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: Infants receiving a standard infant formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding arm
Description: Infants exclusively or predominantly breastfed (\>75%).
Study: NCT01568294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
Study: NCT00595491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage
Description: Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
Study: NCT01994044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical fusion
Study: NCT03255577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Description: Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
Study: NCT04158583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7296682
Description: RO7296682 will be administered by the schedules specified in the respective arms.
Study: NCT02742545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MayoExpertAdvisor
Description: Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
Study: NCT03753555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 20mg Qd for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 40-80mg Qd for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: 0.5g Bid for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: Evolocumab 140mg subcutaneously injected, twice each month